MediciNova Announces Update and Basic Characteristic Randomized Patients' of Phase 2/3 Clinical Trial of MN-166 (Ibudilast) in ALS (COMBAT-ALS Clinical Trial) Presented at the 36th International Symposium on ALS/MND

Stock Information for MediciNova Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About MediciNova Inc.

Message from the CEO to MediciNova Shareholders
MediciNova Appoints Dr. Christopher Breder, MD, PhD as Clinical and Regulatory Advisor
MediciNova Wins Contract Research and Development Innovation Award at 2025 BioTech Breakthrough Awards
MediciNova Announces Completion of Patient Enrollment in MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)
MediciNova Compounds Demonstrate Novel Therapeutic Approach for Atherosclerosis in Peer-Reviewed Publication
MediciNova to Present at the LD Micro Main Event XIX Investor Conference
MediciNova Announces Completion of Patient Enrollment in COMBAT-ALS Phase 2b/3 Clinical Trial of MN-166 (ibudilast)
MediciNova Announces Poster Presentation of COMBAT-ALS Clinical Trial at the 36th International Symposium on ALS/MND

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.